Patients with BCR-ABL1 values >10% at 3 months had better outcomes if the BCR-ABL1 halving time was ≤76 days. Among the 95 patients with BCR-ABL1 values >10%, the 74 patients with a halving time of ≤76 days had significantly superior (A) OS, (B) PFS, (C) FFS, and (D) MMR compared with the 21 patients with a halving time of >76 days. For some of the patients with an assigned halving time of >76 days, their BCR-ABL1 value did not halve at any time or increased. The outcome for patients with BCR-ABL1 values ≤10% at 3 months are also plotted.